[1]

Eyetech Pharmaceuticals
New York, NY
Founded: 2000
http://www.eyetk.com/ [2]

Why It’s Fierce: Eyetech is the exception that proves the rule academics cannot run a company. New York University medical school professor David Guyer and Harvard medical school associate professor Anthony Adamis signed a $745 million collaboration with Pfizer in December to develop Macugen, an anti-vascular endothelial growth factor for age-related macular degeneration and diabetic macular edema. What will Eyetech do for an encore?

What to look for in 2003: The company expects to file a new drug application for Macugen in the coming months.